KMYY(SH:600518) Zheng Quan Zhi Xing·2025-07-04 16:22Core Viewpoint - The legal opinion letter from Guangdong Xinda Law Firm confirms that Kangmei Pharmaceutical Co., Ltd.'s plan to repurchase and cancel unvested restricted stocks under its first and second stock incentive plans complies with relevant laws and regulations [4][6][8]. Summary by Sections Repurchase and Cancellation Conditions - The decision to terminate the first and second stock incentive plans and repurchase unvested restricted stocks is based on the provisions of the Management Measures and has been approved by the company's board and shareholders [4][6]. Decision-Making Process and Information Disclosure - On September 14, 2021, the company held meetings to approve the termination of the first and second stock incentive plans and the repurchase of unvested stocks, with independent directors expressing agreement [6][7]. - The company disclosed the resolutions through official announcements [7]. Involved Parties, Share Quantity, and Cancellation Date - The repurchase involves 816 incentive recipients [8]. - The total number of shares to be repurchased and canceled is 34.97 million shares [8]. - The company has applied for the necessary procedures with the China Securities Depository and Clearing Corporation [8]. Conclusion - The legal opinion concludes that the repurchase and cancellation process meets all necessary legal and regulatory requirements [8].